Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q3 FY23 results · Oct–Dec 2022
Lincoln Pharmaceuticals reported revenue from operations of ₹133.77 crore and net profit of ₹21.61 crore for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 133.77 | — | — | 140.61 | −4.9% |
| Other income | 6.36 | — | — | 5.72 | +11.1% |
| Total income | 140.12 | — | — | 146.33 | −4.2% |
| Profit before tax | 30.51 | — | — | 32.06 | −4.8% |
| Net profit for the period | 21.61 | — | — | 23.71 | −8.9% |
| EPS, basic (₹) | 10.79 | — | — | 11.84 | −8.9% |
| Net margin (%) | 16.2 | — | 16.9 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 133.77 | 119.88 | +11.6% | 140.61 | −4.9% |
| Other income | 6.36 | 2.64 | +141.2% | 5.69 | +11.8% |
| Total income | 140.12 | 122.52 | +14.4% | 146.30 | −4.2% |
| Profit before tax | 30.52 | 23.60 | +29.3% | 32.03 | −4.7% |
| Net profit for the period | 21.61 | 17.60 | +22.8% | 23.71 | −8.9% |
| EPS, basic (₹) | 10.79 | 8.79 | +22.8% | 11.84 | −8.9% |
| Net margin (%) | 16.2 | 14.7 | 16.9 |
Consolidated
- Filed with BSE
- 10 Feb 2023, 15:43 IST
- Board meeting
- 09 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Feb 2023, 15:43 IST
- Board meeting
- 09 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE